PHARMACOKINETIC DRUG- DRUG INTERACTIONS BETWEEN ALBUTEROL WITH BETA BLOCKERS TIMOLOL
Abstract
The present study was aimed to conduct to evaluate any possible pharmacokinetic interactions between albuterol and timolol. Study was conducted in Male Wistar rats; animals were divided in to three groups, Group I received albuterol alone in single dose / day in healthy rats. Group 2 received timolol alone in single dose / day in healthy rats. Group 3 received albuterol and timolol concomitant administration in healthy rats as a single dose / day. The treatment was given on day one and day 8 both alone albuterol and timolol concomitantly used both the drugs. There was no significant difference in both cmax, tmax and AUC0-t and AUCo-inf of albuterol alone and combination of timolol on day 1 and day 8 respectively. Based on the results obtained from kinetic study it is evident that the single dose of albuterol and timolol individually and concomitantly treated shows no statistically significant interactions in its pharmacokinetic parameters.
Keywords:
Albuterol, timolol, pharmacokinetic interactions, AUC.DOI
https://doi.org/10.25004/IJPSDR.2017.090606References
2. Alfaro CL, Piscitelli SC. Atkinson AJ, Daniels CE, Dedrick RL, Grudyinllas CU, Markey SP. Eds.; Drug Interactions. In Principles of Clinical Pharmacology; Academic Press: San Diego, CA, USA, 2001; 167–180.
3. Anastasio GD, Cornell KO, Menscer D. Drug interactions: Keeping it straight. Am. Fam. Phys. 1997; 56: 883–894.
4. Hohl CM, Dankoff J, Colacone A, Afilalo M. Poly pharmacy adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann. Emerg. Med. 2001; 38: 666–671.
5. Wright JM. Drug Interactions. In Melmon and Marrelli’s Clinical Pharmacology Basic Principles in Therapeutics, 4th ed.; Carruthors SG, Hoffman BB, Melmon KL, Nierenberg DW, Eds.; McGrow-Hill: New York, NY, USA, 2000; 1257–1266.
6. Hogan MJ, Zucchero FJ, Schulty CD, Curran JP. Drug Store News (Serial Online) August 1999. Available online: http://www.fmdarticles.com (accessed on 20 January 2004.
7. Raherison C, Girodet PO. Epidemiology of COPD. Eur Respir Rev. 2009; 18: 213–21.
8. Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2010; 80:112–9.
9. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring Jr E, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006; 16:63–70.
10. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010; 65:956–62.
11. Hawkins NM, Jhund PS, Simpson CR, Petrie MC, Macdonald MR, Dunn FG, Macintyre K, McMurray JJ. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail. 2010; 12(1): 17–24.
12. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, Comignani PD, Gimeno G, Arakaki D, Laffaye N, Fuselli JJ, Massolin HP, Gambarte J, Romero M, Tognoni G. Unrecognised ventricular dysfunction in COPD. Eur Respir J. 2012; 39(1):51–8.
13. Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, Hoes AW. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005; 26(18):1887–94.
Published
Abstract Display: 363 
PDF Downloads: 492 
